Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336027 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL345737 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL345736 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL617316 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL2591304 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL13860171 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL4390283 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL2942462 | 0.89 | RIPK1 (0.33) | RIPK1LMNA | |
| SCHEMBL4388287 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL23527330 | 0.87 | RIPK1 (0.33) | RIPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20250051343-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2025-02-13 | — | — | US | disclosed |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20220267304-A1 | INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-08-25 | — | — | US | disclosed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| EP-3277677-B1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2059522-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | Brystol-Myers Squibb Company (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051343-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | RIPK1 2997/4885LMNA 2088/4885DPP4 4609/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | RIPK1 644/4885LMNA 1162/4885DPP4 8/4885 |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, MAN2A1, ENGASE | RIPK1 4868/4885LMNA 2855/4885DPP4 143/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | RIPK1 2997/4885LMNA 2088/4885DPP4 4609/4885 |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | CYP19A1, HSD17B11, CYP51A1 | RIPK1 3812/4885LMNA 3572/4885DPP4 2428/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | RIPK1 3457/4885LMNA 3346/4885DPP4 4616/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | RIPK1 436/4885LMNA 4811/4885DPP4 319/4885 |
| US-20220267304-A1 | INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | CYP19A1, HSD17B11, CYP51A1 | RIPK1 3812/4885LMNA 3572/4885DPP4 2428/4885 |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | RIPK1 1022/4885LMNA 2637/4885DPP4 1614/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | RIPK1 3923/4885LMNA 3767/4885DPP4 1451/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | RIPK1 1967/4885LMNA 3845/4885DPP4 1843/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | RIPK1 870/4885LMNA 4038/4885DPP4 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.